Mayne waits for FDA nod as losses rise
SYDNEY: Specialty pharmaceutical company Mayne Pharma Group hopes to get the nod from ...
To read the full story...SUBSCRIBE NOWExisting Subscribers Login Below:
Log In
FEATURED
Australian Turf Club secures Asahi as new beverage partner
Aristocrat Leisure announces gaming portfolio for ICE Barcelona
Kalgoorlie racing season bound for Esperance as water talks break down
AFL and NRL ‘lobbied PM before gambling ad reforms delayed to 2025’
Tabcorp shares surge 6p.c. following strategic leadership appointment